Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Chemical suppressors of nonsense mutations for the treatment of frontotemporal dementia
FY 2016-17
Summary
Frontotemporal dementia (FTD) is a progressive neurodegenerative syndrome that is the second most common cause of early onset dementia after Alzheimer's disease. Approximately 25% of FTD cases are caused by loss-of-function mutations in the progranulin gene (GRN). A nonsense mutation is a type of loss-of-function mutation that causes a protein to be cut short in length by a process known as premature termination. Nonsense mutations in GRN make up approximately 7.5-10% of FTD cases (FTD-GRN). We have discovered small molecules that can silence the effect of nonsense mutations by preventing premature termination, resulting in functional full length protein production. The goal of this proposal is to determine whether these small molecules promote the expression of full-length progranulin protein in cells derived from FTD-GRN patients. If the compounds are successful in patient cells, we will then test them in a mouse model of FTD-GRN caused by a nonsense mutation. Overall, the current compounds capable of nonsense mutation silencing suffer from low and unpredictable activity. Our proposal addresses these limitations with newly discovered nonsense mutation silencing compounds. This work is important because there are currently no effective treatments for FTD. A successful outcome will provide a proof-of-concept for nonsense mutation silencing as a new therapeutic strategy for FTD and a multitude of other diseases caused by nonsense mutations.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367116
Name
Frew Jonathan S
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Chemical suppressors of nonsense mutations for the treatment of frontotemporal dementia
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chemical Suppressor; Disease Modelling; Frontotemporal Dementia; Induced Pluripotent Stem Cells; Nonsense Mutations; Novel Drug Development; Progranulin; Transcription
Abstract
Frontotemporal dementia (FTD) is a progressive neurodegenerative syndrome that is the second most common cause of early onset dementia after Alzheimer's disease. Approximately 25% of FTD cases are caused by loss-of-function mutations in the progranulin gene (GRN). A nonsense mutation is a type of loss-of-function mutation that causes a protein to be cut short in length by a process known as premature termination. Nonsense mutations in GRN make up approximately 7.5-10% of FTD cases (FTD-GRN). We have discovered small molecules that can silence the effect of nonsense mutations by preventing premature termination, resulting in functional full length protein production. The goal of this proposal is to determine whether these small molecules promote the expression of full-length progranulin protein in cells derived from FTD-GRN patients. If the compounds are successful in patient cells, we will then test them in a mouse model of FTD-GRN caused by a nonsense mutation. Overall, the current compounds capable of nonsense mutation silencing suffer from low and unpredictable activity. Our proposal addresses these limitations with newly discovered nonsense mutation silencing compounds. This work is important because there are currently no effective treatments for FTD. A successful outcome will provide a proof-of-concept for nonsense mutation silencing as a new therapeutic strategy for FTD and a multitude of other diseases caused by nonsense mutations.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Frew, Jonathan S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~